GSK has announced that it is delighted with today's verdict by the jury in the Joiner case in Illinois state court, which found in favor of the company.

This result is in line with the scientific consensus that there is no consistent or reliable evidence that Zantac (ranitidine) increases the risk of cancer, as confirmed by 16 epidemiological studies", says GSK, indicating that it will continue to defend itself vigorously against all other claims.

Prior to this verdict, the court had rejected the plaintiff's claim for punitive damages, adds GSK.

Copyright (c) 2024 CercleFinance.com. All rights reserved.